13 completed, 6 terminated, 5 recruiting, 2 not yet recruiting. 28 Phase 3, 7 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 28 | Completed 13, Terminated 6, Recruiting 5, Not yet recruiting 2, Withdrawn 2 |
| Phase 2 | 7 | Recruiting 3, Completed 2, Terminated 2 |
Follow Status Epilepticus: new trials by email Literature Review of Status Epilepticus trials Research Report on Status Epilepticus
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| COMparison Between Anakinra and Tocilizumab in NORSE - "COMBAT-NORSE" Anakinra, Tocilizumab, Standard medical treatment - New Onset Refractory Status Epilepticus, New-Onset Refractory Status Epilepticus | Phase 3 | Not yet recruiting | Yale University | 438 | 2026-12-01 | 2026-08-19 |
| Ketamine add-on Therapy for Established Status Epilepticus Treatment Trial (KESETT) Levetiracetam (LEV) (60 mg/Kg) + 1 mg/kg Ketamine (KET), Levetiracetam (LEV) (60 mg/Kg) + 3 mg/kg Ketamine (KET), Levetiracetam (LEV) (60 mg/Kg) - Status Epilepticus | Phase 3 | Recruiting | University of Virginia | 770 | 2026-03-06 | 2026-09-17 |
| Targeted Hypothermia Versus Targeted Normothermia After Convulsive Refractory Status Epilepticus Targeted Hypothermia - Convulsive Refractory Status Epilepticus, Status Epilepticus | Phase 3 | Not yet recruiting | Versailles Hospital | 466 | 2026-03-01 | 2026-02-10 |
| Prehospital Early Administration of Ketamine for Status Epilepticus in Epileptic Kids (PEAK-SEEK) Ketamine, Midazolam - Convulsive Status EPILEPTICUS | Phase 2 / Phase 3 | Recruiting | Sohag University | 668 | 2025-08-03 | 2025-08-05 |
| Ketamine and Levetiracetam as Second-line Antiseizure Medication for Status Epilepticus in Children Ketamine, Levetiracetam, Placebo - Generalized Convulsive Status Epilepticus | Phase 2 / Phase 3 | Recruiting | Sohag University | 124 | 2025-07-02 | 2025-07-03 |
| To Evaluate the Efficacy, Safety, and Tolerability of Intravenous Ganaxolone Added to Standard of Care in Refractory Status Epilepticus (RSE) Ganaxolone, Placebo, Standard of care - Refractory Status Epilepticus | Phase 3 | Withdrawn | Marinus Pharmaceuticals | 2024-03-01 | 2024-05-14 | |
| Combined Ketamine and Midazolam for Generalized Convulsive Status Epilepticus Ketamine, Midazolam, Placebo - Generalized Convulsive Status Epilepticus | Phase 2 / Phase 3 | Completed | Sohag University | 144 | 2023-03-21 | 2024-10-29 |
| Exogenous Ketone Esters for Refractory Status Epileptics Exogenous ketone ester - Status Epilepticus | Phase 2 / Phase 3 | Recruiting | Sohag University | 50 | 2023-01-10 | 2024-11-27 |
| Fast Acute Sedation at Intensive Care vs. High-dose i.v. Anti-seizure Medication for Treatment of Non-convulsive Status Epilepticus (FAST-trial) Rapid sedation - Non-Convulsive Status Epilepticus | Phase 3 | Recruiting | University of Southern Denmark | 140 | 2022-02-07 | 2026-05-04 |
| Randomized Therapy In Status Epilepticus Ganaxolone, Placebo - Status Epilepticus | Phase 3 | Completed | Marinus Pharmaceuticals | 100 | 2020-12-09 | 2025-05-29 |
| A Study to Evaluate Efficacy and Safety of Vatiquinone for Treating Mitochondrial Disease in Participants With Refractory Epilepsy Vatiquinone, Placebo - Mitochondrial Diseases, Drug Resistant Epilepsy | Phase 2 / Phase 3 | Terminated | PTC Therapeutics | 68 | 2020-09-28 | 2026-03-31 |
| Efficacy Study of Acetazolamide Versus Diazepam in Continuous Spike and Wave/Landau-Kleffner Syndrome Diazepam, Acetazolamide - Landau-Kleffner Syndrome, Status Epilepticus, Electrographic | Phase 2 / Phase 3 | Terminated | Mayo Clinic | 3 | 2016-09-01 | 2020-06-11 |
| Established Status Epilepticus Treatment Trial Fosphenytoin, Levetiracetam, Valproic acid - Benzodiazepine Refractory Status Epilepticus | Phase 3 | Completed | University of Virginia | 478 | 2015-10-01 | 2021-06-14 |
| Ketamine in Refractory Convulsive Status Epilepticus Ketamine - Status Epilepticus | Phase 3 | Terminated | Meyer Children's Hospital IRCCS | 57 | 2015-04-01 | 2020-10-08 |
| Lorazepam for the Treatment of Status Epilepticus or Repetitive Status Epilepticus in Japan Lorazepam - Status Epilepticus | Phase 3 | Completed | Pfizer | 26 | 2014-11-01 | 2019-02-18 |
| Clobazam Use in Epilepsia Partialis Continua - Pilot Study Clobazam, Clonazepam, Lorazepam - Epilepsia Partialis Continua, Kojewnikov's Epilepsy | Phase 3 | Terminated | The Cooper Health System | 7 | 2014-07-01 | 2018-05-09 |
| Levetiracetam, Lacosamide and Ketamine as Adjunctive Treatment of Refractory Status Epilepticus levetiracetam, lacosamide, Ketamine - Epilepsy, Status Epilepticus | Phase 3 | Withdrawn | Mid-Atlantic Epilepsy and Sleep Center, LLC | 2014-02-01 | 2017-08-29 | |
| Comparison Between Lorazepam, Clonazepam and Clonazepam + Fosphenytoin for the Treatment of Out-of-hospital Generalized Status Epilepticus Clonazepam, Fosphenytoin, Placebo - Status Epilepticus, Epilepsy | Phase 3 | Completed | Assistance Publique - Hôpitaux de Paris | 434 | 2013-06-26 | 2018-10-11 |
| Evaluation of Therapeutic Hypothermia in Convulsive Status EPILEPTICUS in Adults in Intensive Care Moderate hypothermia - Convulsive Status EPILEPTICUS | Phase 3 | Completed | Assistance Publique - Hôpitaux de Paris | 270 | 2010-12-01 | 2016-09-29 |
| Refractory Status Epilepticus Treatment Study valproic acid (VPA) - Grand Mal Status Epilepticus, Non-convulsive Status Epilepticus | Phase 3 | Completed | Hospital Universitari de Bellvitge | 5 | 2010-01-01 | 2013-03-12 |
Showing 20 of 28. Sign in to see all of them.
Seizures (10) · Epilepsy (5) · Diffuse Cerebral Sclerosis of Schilder (1) · Drug Resistant Epilepsy (1) · Epilepsia Partialis Continua (1) · Epilepsy, Partial, Motor (1) · Landau-Kleffner Syndrome (1) · Leigh Disease (1) · MELAS Syndrome (1) · MERRF Syndrome (1) · Mental Disorders (1) · Mitochondrial Diseases (1) · Mitochondrial encephalopathy (1) · Nerve Degeneration (1)
Nervous System Diseases (28) · Pathological Conditions, Signs and Symptoms (28) · Signs and Symptoms (28) · Neurologic Manifestations (27) · Seizures (18) · Brain Diseases (7) · Central Nervous System Diseases (7) · Epilepsy (2) · Epileptic Syndromes (2) · Pathologic Processes (2) · Autoimmune Diseases (1) · Autoimmune Diseases of the Nervous System (1) · Brain Diseases, Metabolic (1) · Brain Diseases, Metabolic, Inborn (1) · Carbohydrate Metabolism, Inborn Errors (1)
Lorazepam (8) · Ketamine (6) · Levetiracetam (5) · Clonazepam (3) · Diazepam (3) · Hypothermia, Induced (2) · Midazolam (2) · Valproic Acid (2) · fosphenytoin (2) · ganaxolone (2) · Acetazolamide (1) · Benzodiazepines (1) · Clobazam (1) · Interleukin 1 Receptor Antagonist Protein (1) · Lacosamide (1)
Sohag University (4) · Assistance Publique - Hôpitaux de Paris (3) · Kamuzu University of Health Sciences (2) · Marinus Pharmaceuticals (2) · University of Virginia (2) · All India Institute of Medical Sciences (1) · Brigham and Women's Hospital (1) · Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) (1) · Hospital Universitari de Bellvitge (1) · Mayo Clinic (1) · Meyer Children's Hospital IRCCS (1) · Mid-Atlantic Epilepsy and Sleep Center, LLC (1) · National Institute of Neurological Disorders and Stroke (NINDS) (1) · PTC Therapeutics (1) · Pfizer (1)
United States (11) · France (7) · Canada (4) · Egypt (4) · Italy (4) · Spain (3) · United Kingdom (3) · Japan (2) · Malawi (2) · Poland (2) · Sweden (2) · Switzerland (2) · Australia (1) · Austria (1) · Belgium (1)
Abdelrahim A Sadek, MD, PhD (2) · James Chamberlain, MD (2) · Robert Silbergleit, MD (2) · Andrea O. Rossetti, MD (1) · Anna Rosati, MD, PhD (1) · Daniel H Lowenstein, MD (1) · Daniel Lowenstein (1) · Elizabeth Molyneux (1) · Elizabeth Molyneux, MRCPCH FFAEM (1) · Jaideep Kapur, MBBS, PhD (1) · Jaideep Kapur, MD, PhD (1) · Jordan Elm, PhD (1) · Katherine C. Nickels, M.D. (1) · Lawrence Hirsch, MD (1)
PMID 16698412, PMID 20878265, PMID 21275979, PMID 21967361, PMID 21967362, PMID 22335736, PMID 22506949, PMID 24001080, PMID 24756515, PMID 26627366, PMID 27311915, PMID 27325409, PMID 27993298, PMID 28002714, PMID 30232735, PMID 31161706, PMID 31774955, PMID 32203691, PMID 32446674, PMID 32913029, PMID 33336359, PMID 33567109, PMID 33742783, PMID 34032604, PMID 35718575, PMID 35987977, PMID 37286846, PMID 40953286
2017 (1), U01NS056975 (1), U01NS088034 (1)